



Minutes of the Integrated Medicines Optimisation Committee (IMOC)
Held on Wednesday 1st April 2026 11:30-13:30
Via Microsoft Team

Attendees present:	Time of attendance (if not present for full meeting)	Invited Attendees:	
✓		David Warwicker (DW)	Medical Lead for Medicines Optimisation (chair)
		Heidi Taylor (HT)	SYICB Medicines Optimisation Programme Director (Clinical Effectiveness, Quality and Safety)
		Alex Molyneux (AJM)	NHS SY ICS Chief Pharmacy Officer
✓		Chris Bland (CB)	Chair Community Pharmacy South Yorkshire (CPSY)
✓		Govinder Bhogal (GOVB)	Programme Director for Medicines Optimisation (Pathways Redesign and Population Health)
		Chris Lawson (CL)	SYICB Medicines Optimisation Programme Director (Strategy & Delivery)
		Charlotte McMurray (CM)	SYICB Medicines Optimisation Programme Director (Pharmacy Integration and Development)
✓		Ashley Hill (AH)	SYICB Senior Medicines Optimisation Technician- Doncaster (IMOC Secretary)
		Esoop Bharoocha (EB)	SYICB Deputy Chief Pharmacist – Rotherham Hospital

✓		Dean Eggitt (DE)	LMC representative – Doncaster
✓		Rob Wise (RW)	Senior Pharmacist NNICB - Bassetlaw Place Partnership
		Krishna Kasaraneni (KK)	LMC Representative – Sheffield
✓		Lee Wilson (LW)	Consultant Pharmacist DBTHFT
✓		Sarah Hudson (SH)	Deputy Chief Pharmacist SWYPFT
		Joanne Wragg (JW)	Sheffield Children’s NHS FT Chief Pharmacist
✓		Barbara Obasi (BO)	Senior Pharmacist (Pharmacy Integration and Development Portfolio)
		Abiola Allinson (AA)	SYICB Chief Pharmacist- SHSC
		Steve Davis (SD)	RDaSH Chief Pharmacist
		Claire Thomas (CT)	Community Pharmacy Clinical lead- SY ICB
		Graham Marsh (GM)	Sheffield Teaching Hospital Chief Pharmacist
		Mr Veeraraghavan Chidambaram-Nathan (CN)	Transplant and General surgery Consultant - STH
✓		Trish Edney (TE)	Sheffield Healthwatch Representative
		Eloise Summerfield (ES)	Senior Pharmacist (Strategy & Delivery) Rotherham Place Support to High-Cost Drugs (Pathways)
		Deborah Cooke (DC)	Senior Pharmacist (Strategy and Delivery & Clinical Effectiveness- Barnsley Place)
		Gillian Turrell (GT)	SYICB- Hospital Pharmacist- Barnsley
✓		Sophie Holden (SH)	Rotherham GP MM lead for Rotherham Place
		Jason Page (JP)	Rotherham Place Medical Director
✓		Joanne Howlett (JH)	Medicines Optimisation Lead Pharmacist (Strategy and Delivery – Barnsley Place)
		Paul McManus (PM)	NHSE Specialist commissioning - Senior Pharmacist
✓		Ewa Gabzdyl (EG)	Senior Pharmacist Strategy & Delivery- Doncaster Place
✓		Surinder Ahuja (SA)	Medication Safety Officer & Lead Pharmacist Governance and Formulary- Rotherham Hospital
✓		Shameila Afsar -Baig (SAB)	Senior Pharmacist (Strategy and Delivery)- Sheffield Place

✓		Kulsoom Khan (KKh)	Procurement Pharmacist at TRFT
✓		Mallicka Chakrabarty (MC)	GP Prescribing Lead (Bassetlaw)
		Navjit Johal (NJ)	Chief Pharmacist – Rotherham Hospital
✓		Robina Okes-Voysey (ROV)	Senior Pharmacist, Quality Improvement
✓		Bipin Chandran (BC)	Rotherham LMC representative
		Greg Westley (GW)	Medicines Safety Officer
✓		Helen Cunningham (HC)	Medicines Optimisation Team Lead Technician (Integration and Development; Strategy and Delivery Doncaster)
✓		Lisa Eccles (formerly Murray) (LE)	Lead Pharmacist (Strategy and Delivery-Rotherham)
✓		Sharron Kebell (SK)	Senior Pharmacist - High cost Drugs Pathways

		Action
1	<p>Welcome:</p> <p>Welcome to Helen Cunningham - who is currently temporary filling in Laura's position as medicines safety technician, is just observing today</p> <p>Sharron Kebell – Presenting the NICE Document</p>	
	<p>Apologies</p> <p>Charlotte McMurray, Heidi Taylor, Alex Molyneux , Greg Westley , Abiola Allinson, Jason Page, Deborah Cooke, Chris Lawson</p>	
2	<p>Declarations of Interest (DOI)</p> <p>The Chair reminded committee members of their obligation to declare any interest they may have on any issues arising at committee meetings which might conflict with the business of the South Yorkshire Integrated Care Board (ICB).</p> <p>Declarations declared by members are listed in the ICB Register of Interests. The register is available on the ICB website at the following link: https://southyorkshire.icb.nhs.uk/about-us/our-structure/register-interests</p> <p>None were given</p>	
3	<p>Notification of Any Other Business</p> <p>None were given</p>	
4	<p>Minutes of the meeting held on 4th March 2026 & any other items which are not on the agenda</p>	

	<p>The minutes were taken as a true reflection of the meeting and were approved.</p> <p>Action: AH to upload ratified minutes to the medicines optimisation website and circulate.</p>	AH
5	<p>Action Log & Matters arising</p> <p>The required actions were duly recorded in the action log.</p>	
6	<p>ICB Formal Executive Group Report (FEG)</p> <p>AH informed the committee that March's IMOC decisions went to the formal executive group meeting which were all acknowledged and supported.</p>	
11	<p>Horizon Scanning</p> <p>All drugs included in the list were approved and recorded in the summary below. Highlighting Optimise Rx and Script switch can be used to notify prescribers with recommendations required.</p>	
12	<p>IMOC subgroup TLDL</p> <p>The committee approved the IMOC sub group drugs and these have been recorded in the summary below.</p>	
13	<p>NICE Summary</p> <p>NICE TA1140- Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. Currently traffic lighted as Grey, will be updated to Red in line with positive NICE TA's. NICE impact assessment suggests 205 patients in year 1. Cost is £657 for 1x 100 g tube – but there is a confidential discount available</p>	

(No more than two tubes of 100 grams a month should be used.) SK informed the committee that she had spoken to the Sheffield's Dermatology specialist who could not comment on potential patient numbers or when they will be initiating patient on the treatment. This is a high-cost drug which is excluded from tariff and will have cost implications to the ICB.

[NICE TA878](#)- Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19. Already traffic lighted Red. Remove Sotrovimab from the SY traffic light list as this has now been discontinued.

[NICE HST35](#)- Pegzilarginase for treating arginase-1 deficiency in people 2 years and over. Currently traffic lighted as Grey. Changed traffic light status to Red in line with positive NICE TA's

[NICE TA1136](#)- Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Already traffic lighted as Red.

[NICE TA1138](#)- Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer. Already traffic lighted as Red.

[NICE TA1139](#)- Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment. Currently has dual traffic light status Grey and Red. The committee agreed one traffic light status of Red in line with positive NICE TA's

[NICE TA 1141](#)- Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal). Nivolumab is already traffic lighted Red in line with positive NICE TA's.

[NICE TA 1137](#)- Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). Canagliflozin for treating type 2 diabetes is already traffic lighted Green for use in adults.

Actions:

	<ul style="list-style-type: none"> • AH to update SY traffic light drug list • Places to update their formularies if required 	
14	<p>Safety updates minor updates to existing guidance documents</p> <p>The following safety updates were discussed and approved:</p> <p><u>"Crescent Pharma Limited, Ramipril 5mg capsules</u></p> <p><u>Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure due to a potential error at the manufacturing site. Crescent Pharma Limited has received one complaint to date, where it has been identified that a pack of Ramipril 5mg capsules contains blister strips of Amlodipine 5mg tablets inside the sealed carton."</u></p> <p>-Pharmacies are required to identify and contact patients dispensed the product between 06 June 2025 and 06 March 2026, if batch traceability is not available.</p> <p>If patients are found to hold affected stock, primary care clinicians may need to review the patient, reassure on expected low harm and provide a new prescription for Ramipril where ongoing treatment is required."</p> <p><u>"Urgent Public Health Message – Outbreak of Invasive Meningococcal Disease, South East England</u></p> <p><u>The alert outlines recommended courses of action to manage cases with infection and contacts."</u></p> <p>-For information only. No actions for South Yorkshire.</p> <p>Actions:</p> <ul style="list-style-type: none"> • MOT to take back to Place meetings to review and action as recommended in the safety update 	

17	Minutes from SY ICB place APCs and other documents for circulation None were discussed	
18	Stock Shortages None were discussed	
19	Items for Escalation (e.g. commissioning requirements) Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. This is a high-cost drug which is excluded from tariff and will have cost implications to the ICB.	
20	Workplan / Forward Planner/ action log AH Updated the committee that the migraine pathway could now be closed as there are no further actions.	
21	Any other Business None were discussed	
22	Date and Time of Next Meeting Wednesday 6 th May 2026 11:30am Via Microsoft Teams	

Summary Points and Recommendations approved
April's 2026

<u>Approved Guidelines/ Shared Care protocols:</u>	<ul style="list-style-type: none"> • None were discussed this month
---	--

Drug/Product Traffic Light Status	Brand name	Rationale / criteria	Indication	Date Considered	Review date	Comments	Agenda Item
Potassium citrate (new modified- release tablet formulation with new indication)	Renodyra®	1	Use in <u>adults</u> for the treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones; the treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis; the treatment of renal tubular acidosis with calcium nephrolithiasis	Apr-26			

			whom chemotherapy is not clinically indicated				
Pneumococcal polysaccharide conjugate vaccine (new vaccine)	Capvaxive®		Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 years and older	Apr-26		Pneumococcal: the Green Book, Chapter 25	Horizon Scanning
Mirvetuximab soravtansine (new medicine) not traffic lighted will be traffic lighted at May's IMOC meeting	Elahere®		Use as monotherapy for the treatment of adults with folate receptor-alpha-positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens	Apr-26		<i>To be classified at IMOC on publication of NICE TA (expected May 2026)</i>	Horizon Scanning
Tisotumab vedotin (new medicine) not traffic lighted will be traffic lighted at May's IMOC meeting	Tivdak®		Use as monotherapy for the treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy	Apr-26		<i>To be classified at IMOC on publication of NICE TA (expected May 2026)</i>	Horizon Scanning
Gelatin	(Gelaspan®)	1,5	Plasma substitute	Apr-26			IMOC subgroup
IV nutrition products		1,5	Intravenous nutrition	Apr-26			IMOC subgroup
Isosorbide dinitrate injection		1,5	Emergency Treatment of Poisoning (hypertension)	Apr-26			IMOC subgroup

Sodium Chloride oral solution	1,5	Oral sodium	Apr-26			IMOC subgroup
Vancomycin inj	1,5		Apr-26			IMOC subgroup
Levofloxacin-Infusion, solution for infusion, nebuliser liquid & eye drops	1,5	All licensed indications	Apr-26		We approved at March's IMOC forms of medication queried. Currently traffic lighted Green for tablets red for all other forms and indications	IMOC subgroup
Ruxolitinib cream	1,5	for treating non-segmental vitiligo in people 12 years and over	Apr-26		was traffic lighted Grey - all Ruxolitinib formulation to be traffic lighted Red for positive NICE TA's Only NICE TA1140	NICE TA
Nirmatrelvir plus ritonavir and tocilizumab	1,5	for treating COVID-19	Apr-26		NICE TA878	NICE TA
Sotrovimab		for treating COVID-19	Apr-26		<u>This has now been discontinued - To be removed off TLDL</u>	
Pegzilarginase	1,5	for treating arginase-1 deficiency in people 2 years and over	Apr-26		was traffic lighted Grey. Now TLS changed to red in line with positive NICE TA's	NICE TA
Bevacizumab	1,5	(originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer	Apr-26		NICE TA 1136- already traffic lighted	NICE TA
Durvalumab with gemcitabine and cisplatin	1,5	for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer	Apr-26		NICE TA 1138- already traffic lighted	NICE TA
Epcoritamab	1,5	for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment	Apr-26		NICE TA 1139- Red for positive NICE TA's	NICE TA

Nivolumab			Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)	Apr-26		NICE TA 1141- Terminated appraisal. Nivolumab traffic lighted Red for positive NICE TA's	NICE TA
Canagliflozin			for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)	Apr-26		NICE TA 1137- Terminated appraisal for this indication. Traffic lighted Green in line with positive NICE TA's	NICE TA